{
}
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight loss drug, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner. This decision follows positive study results indicating that the high-dose weight loss drug Wegovy leads to greater weight loss compared to lower doses, according to analyst Jo Walton.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish kroner. This decision follows positive study results indicating greater weight loss with the high-dose version of the weight loss drug Wegovy compared to lower doses.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton believes the recent share price reaction to the Phase III results of the CagriSema study is exaggerated, presenting an attractive entry point for investors.
UBS analyst Jo Walton upgraded Novo Nordisk from a Sell to a Buy rating, adjusting the price target to DKK750.00 from DKK1,100.00, citing expectations for increased demand for GLP-1 medications. Despite slower growth in prescriptions, Walton remains optimistic about the company's prospects, particularly with the anticipated demand surge in early 2025 and the potential of CagriSema as an effective treatment for obesity and type-2 diabetes.
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton highlighted disappointing results for the weight loss drug Cagrisema, which showed a 20.4% reduction, falling short of the expected 25%. Future focus may shift towards availability, tolerability, and convenience of oral administration rather than efficacy.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a slight increase in first-time prescriptions for weight-loss drugs in the US, based on data up to December 6.
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a price target of 1100 Danish crowns. This decision reflects recent trends in prescription rates for weight-loss drugs in the USA, as noted by analyst Jo Walton in a study published on December 9, 2024.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Despite the reavailability of the weight loss drug Wegovy, analyst Jo Walton noted a lack of significant demand increase in the US market.
Jo Walton
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for novo nordisk with target price of 750 kroner
08:04 21.01.2025
ubs maintains buy rating for novo nordisk with positive wegovy study results
17:08 17.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
16:56 17.01.2025
UBS maintains buy rating for Novo Nordisk with target price of 750 crowns
Danish Krone
Novo Nordisk A/S
CHE
DNK
Hubert Dichtl
Thomas Müller
Warren Buffett
Jo Walton
Show more
12:21 16.01.2025
ubs upgrades novo nordisk to buy amid positive glp-1 demand outlook
10:38 08.01.2025
novo nordisk faces stock plunge after disappointing results for obesity drug
Danish Krone
Catalent, Inc.
Novo Nordisk A/S
Eli Lilly and Company
DNK
Florent Cespedes
Emmanuel Papadakis
Jo Walton
Peter Welford
Show more
15:35 20.12.2024
ubs maintains neutral rating on novo nordisk amid disappointing weight loss data
15:17 20.12.2024
UBS Maintains Neutral Rating for Novo Nordisk with Target Price of 1100 Kroner
15:24 16.12.2024
UBS Maintains Neutral Rating for Novo Nordisk with 1100 Kroner Target
17:19 09.12.2024
ubs maintains neutral rating for novo nordisk amid stagnant demand for wegovy
15:13 02.12.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Central Bank Actions
Finance Mergers & Acquisitions
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Government Economic Policies
CEO Changes
Market Analysis and Predictions
Domestic Politics
Government Policies
Workplace Trends
GDP Growth & Recession Forecasts
Financial Scams and Security
Countries:
Companies:
Tesla, Inc.
Apple Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
Credit Suisse Strategic Income I
Banco Santander, S.A.
Berkshire Hathaway Inc.
SpaceXCoin USD
Bank of America Corporation
Morgan Stanley
BNP Paribas SA
Amazon.com, Inc.
UBS Group AG
Lloyds Banking Group plc
NVIDIA Corporation
Bank Frick AG
Citigroup Inc.
Wells Fargo & Company
Currencies:
United States Dollar
Euro
British Pound Sterling
Japanese Yen
Swiss Franc
Indian Rupee
Chinese Yuan
South Korean Won
Vietnamese Đồng
Canadian Dollar
Australian Dollar
Thai Baht
Indonesian Rupiah
Singapore Dollar
Mexican Peso
New Taiwan Dollar
Russian Ruble
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
People: